Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of MTC001 in chronic ischemic heart failure
jRCT2033210078Phase 1Suspended
- Sponsor
- Metcela Inc.
- Start
- Jul 2022
- Modality
- Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MTC001 in ischaemic cardiomyopathy (ICM) and myocardial infarction (MI), sponsored by Metcela Inc. Primary endpoint: Major cardiovascular events. Started Jul 2022; status: suspended.
02
Drugs
MTC001
03
Conditions
ischaemic cardiomyopathy (ICM)myocardial infarction (MI)
Beyond the preview
Go deeper on jRCT2033210078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033210078.